Quantitative Systems Toxicology Approach Integrates Simcyp PBPK and Core Hepatocyte Metabolism: a Case Study with Valproic Acid
0 comments.
Click here to read/write comments.
Topics:
Solution: PBPK Modeling & Simulation
Prediction of mAb disposition in hepatic impairment – Evolocumab as a case study
0 comments.
Click here to read/write comments.
Topics:
Use of a physiologically based pharmacokinetic – pharmacodynamic (PBPK-PD) model to guide dose adjustments to S-warfarin in different populations
0 comments.
Click here to read/write comments.
Topics:
Biopharmaceutic In Vitro In Vivo Extrapolation (IVIV_E) Informed PBPK Model of Ritonavir Norvir® Tablet Absorption in Humans Under Fasted and Fed State Conditions
0 comments.
Click here to read/write comments.
Topics:
Accounting for CYP2C19 mechanism based inhibition and CYP1A2 induction in a PBPK model for omeprazole
0 comments.
Click here to read/write comments.
Topics:
Physiological verification of a geriatric population using the Simcyp R package
0 comments.
Click here to read/write comments.
Topics:
Estimation of Effective pKa of Bicarbonate Buffer
0 comments.
Click here to read/write comments.
Topics:
Quantification of Human Blood-Brain Barrier Transporters in Health and in Dementia by Global and Targeted Proteomics
0 comments.
Click here to read/write comments.
Topics:
The Molecular Stethoscope: RNA of Drug Metabolising Enzymes in Circulating Vesicles Correlates with their Specific Protein Content in the Liver
0 comments.
Click here to read/write comments.
Topics:
Propofol: A Tail of Drug Disposition and Dynamics in Different Dog Breeds
0 comments.
Click here to read/write comments.
Topics:
Simcyp: 20 Years of Innovation
The consortium members have partnered with Simcyp and Certara during the past 20 years to advance the science of drug development through modeling & simulation
Read More
0 comments.
Click here to read/write comments.
Topics:
Supporting Efficient Infectious Disease Drug Development and Commercialization
Certara uses a unique set of disciplines and technologies to address the challenges that infectious disease drug programs face.
Read More
0 comments.
Click here to read/write comments.
Topics:
A Population-based PBPK Model for the Prediction of Time-varying Bile Salt Disposition within GI Luminal Fluids – Toward a Mechanistic Model
0 comments.
Click here to read/write comments.
Topics:
Development of a PBPK model for topical lidocaine in order to predict systemic absorption in healthy volunteers, geriatrics and paediatrics
0 comments.
Click here to read/write comments.
Topics:
Predicting the Concentration of PARP Inhibitors in Human Tumor Tissue Using PBPK Modeling
0 comments.
Click here to read/write comments.
Topics:
Performance Verification and Application of a Cancer population for use in Physiologically Based Pharmacokinetic modelling
0 comments.
Click here to read/write comments.
Topics:
Evaluation of maternal drug exposure following the administration of antenatal corticosteroids during late pregnancy using PBPK Modeling
0 comments.
Click here to read/write comments.
Topics:
INVESTIGATING THE IMPACT OF ENZYME CORRELATIONS ON INTER-INDIVIDUAL VARIABILITY IN PHARMACOKINETICS AND DRUG-DRUG INTERACTIONS
0 comments.
Click here to read/write comments.
Topics:
Biokinetic and PBPK modelling to support the rotenone and strobilurin read across case studies (CS4)
0 comments.
Click here to read/write comments.
Topics:
Biokinetic and PBPK Modelling to Support Read-Across Assessment of Repeat Dose and Developmental and Reproductive Toxicity of Valproic Acid Analogues
0 comments.
Click here to read/write comments.
Topics: